Locations:
March 19, 2018/Cancer

New AJCC TNM Edition More Accurately Predicts Recurrence in Pulmonary Carcinoid Tumors

Turn to 8th edition for better correlation

PrimaryPulmonaryCarcinoid

By Josephine Dermawan, MD, PhD, and Carol Farver, MD

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Pulmonary carcinoid tumors are the uncommon, clinically indolent relative of non-small cell lung cancer (NSCLC). Because current lung cancer staging guidelines are largely based on data from NSCLC, which is vastly more common, using American Joint Committee on Cancer (AJCC) TNM staging to predict long-term recurrence and survival for carcinoid tumors is unclear at best and controversial for most. Our research team sought to offer some clarity to this controversy through a single-institution study that correlates pathologic stage from both the 7th and 8th editions of the Staging Manual with clinical outcomes for carcinoid tumors. We presented our findings at the 2018 Annual Meeting of the United States and Canadian Academy of Pathology.

We identified 217 surgical lung resection cases from 1995-2015 with a diagnosis of primary lung carcinoid tumors and staged them according to both the 7th and 8th editions of the AJCC TNM Classification of Lung Tumors. We also collected clinical data, including demographics, smoking history, recurrence and survival. Patients with concurrent or preexisting malignancies and/or positive resection margins were excluded.

Of the 181 cases available for clinical follow-up, 16 experienced recurrence (9 percent) and five (3 percent) died with metastatic carcinoid tumor. Atypical carcinoid tumors were more significantly likely to recur (log-rank P < 0.0001). Because the 8th edition of TNM places more emphasis on tumor size, staging based on this edition was more likely than the 7th edition to predict outcomes in our study (P < 0.0001 vs P = 0.0026). Procedure type and smoking history did not correlate with outcomes.

Advertisement

Based on our study, we recommend the criteria in the 8th edition of AJCC’s TNM Classification of Lung Tumors for stating primary lung carcinoid tumors. Classifying carcinoid tumors based on typical versus atypical histology types, which is based on mitotic figure counts on histology, is still the best predictor of tumor recurrence. We are currently examining the applicability of the ki67 proliferative index as another tool for classifying this tumor and predicting tumor recurrence.

Advertisement

Related Articles

Dr. Anwer and colleagues
November 12, 2026/Cancer/Blood Cancers

FDA Approval of Iberdomide Marks Historic Milestone in Multiple Myeloma

CELMoD therapy receives approval based primarily on measurable residual disease

Dr. Dedousis
November 2, 2026/Cancer/Podcast

Expanding Germline Genetic Testing in Oncology (Podcast)

Are we missing patients?

Dr. Hanlee Chung
October 29, 2026/Cancer/Podcast

Redefining Resectability in Advanced Rectal Cancer (Podcast)

Expanding treatment options for patients with advanced and recurrent rectal cancer

Patient and healthcare providers
October 28, 2026/Cancer/Patient Support

Desire for Preventative Screening is Strong Among People Experiencing Homelessness

Study analyzes creative approaches to support people facing housing insecurity

AI tech
October 26, 2026/Cancer/Innovations

AI Task Force Develops Unified Strategy to Integrate Tech Innovations

Evaluating AI initiatives and their impact on operations and care delivery

DNA test
October 23, 2026/Cancer/News & Insight

Early Genetic Testing Linked to Bilateral Mastectomy in Young BRCA Carriers with Breast Cancer

Study reinforces the importance of genetic testing prior to local therapy decisions

Dr. Arun Singh
October 21, 2026/Cancer

Preserving Vision in Uveal Melanoma (Podcast)

Understanding expanding treatment options and potential advances

Patient and doctor
October 9, 2026/Cancer/News & Insight

First Radioligand Therapy Approved for Metastatic Hormone-Sensitive Prostate Cancer

Adding 177Lu-PSMA-617 to ADT plus an ARPI cut the risk of radiographic progression or mortality by 28%

Ad